Skip to main content

Brainstorm Cell Therapeutics Inc.

BCLI
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001137883

No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

13F holders, Q1 2022

Institutional positions in Brainstorm Cell Therapeutics Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
39
−2 vs. Q4 2021
Shares held
4.16M
−237.2K (−5.4%) vs. Q4 2021
Total value
$14.0M
−$3.61M (−20.5%) vs. Q4 2021
New holders
5
10 more added
Sold out
7
9 more reduced

1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting BCLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2022: 39 institutions
Q1 2021: 75 institutionsQ2 2021: 57 institutionsQ3 2021: 52 institutionsQ4 2021: 42 institutionsQ1 2022: 39 institutionsQ2 2022: 48 institutionsQ3 2022: 42 institutionsQ4 2022: 43 institutionsQ1 2023: 48 institutionsQ2 2023: 57 institutionsQ3 2023: 53 institutionsQ4 2023: 46 institutionsQ1 2024: 47 institutionsQ2 2024: 48 institutionsQ3 2024: 38 institutionsQ4 2024: 34 institutionsQ1 2025: 32 institutionsQ2 2025: 34 institutionsQ3 2025: 5 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ1 2022: $14.0M
Q1 2021: $32.1MQ2 2021: $21.4MQ3 2021: $16.9MQ4 2021: $17.6MQ1 2022: $14.0MQ2 2022: $11.0MQ3 2022: $17.1MQ4 2022: $6.16MQ1 2023: $20.4MQ2 2023: $11.5MQ3 2023: $928.4KQ4 2023: $1.04MQ1 2024: $2.19MQ2 2024: $4.09MQ3 2024: $2.52MQ4 2024: $560.3KQ1 2025: $1.09MQ2 2025: $264.0KQ3 2025: $1.73KQ4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding BCLI and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20255$1.73K
Q2 202534$264.0K
Q1 202532$1.09M
Q4 202434$560.3K
Q3 202438$2.52M
Q2 202448$4.09M
Q1 202447$2.19M
Q4 202346$1.04M
Q3 202353$928.4K
Q2 202357$11.5M
Q1 202348$20.4M
Q4 202243$6.16M
Q3 202242$17.1M
Q2 202248$11.0M
Q1 202239$14.0M
Q4 202142$17.6M
Q3 202152$16.9M
Q2 202157$21.4M
Q1 202175$32.1M

Institutions, Q1 2022

Shares, value and share of portfolio for each institution holding Brainstorm Cell Therapeutics Inc.; share changes are against Q4 2021.

Institutions holding BCLI in Q1 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc1,421,099$4.78M0.00%−9,473−0.7%Reduced
BlackRock Inc.474,510$1.59M0.00%+2,034+0.4%Added
Ikarian Capital, LLC304,161$1.02M0.31%+14,611+5.0%Added
Geode Capital Management, LLC283,485$952.0K0.00%+5,384+1.9%Added
Abner Herrman & Brock LLC265,000$890.0K0.12%+32,000+13.7%Added
JPMorgan Chase & Co246,202$827.0K0.00%+53,036+27.5%Added
Raymond James & Associates190,403$640.0K0.00%+900+0.5%Added
Millennium Management LLC141,253$475.0K0.00%−8,913−5.9%Reduced
Weaver Consulting Group130,000$437.0K0.21%−25,500−16.4%Reduced
State Street Corp96,060$323.0K0.00%+9,357+10.8%Added
Susquehanna International Group, LLP94,600$318.0K0.00%+94,600New
Price T Rowe Associates Inc93,000$312.0K0.00%00.0%Unchanged
Northern Trust Corp55,916$188.0K0.00%−3,175−5.4%Reduced
Group One Trading, L.P.49,097$165.0K0.00%+49,097New
Morgan Stanley49,106$164.0K0.00%−2,554−4.9%Reduced
Jmac Enterprises LLC45,430$153.0K0.04%+45,430New
IFP Advisors, Inc19,850$104.0K0.00%+19,850New
Boothbay Fund Management, LLC29,186$98.0K0.00%00.0%Unchanged
Citadel Advisors LLC24,119$81.0K0.00%+24,119New
Wells Fargo & Company16,225$55.0K0.00%−2,333−12.6%Reduced
S.C. Financial Services, Inc.15,285$51.0K0.07%00.0%Unchanged
Aptus Capital Advisors, LLC12,500$42.0K0.00%00.0%Unchanged
Bank of New York Mellon Corp12,250$41.0K0.00%00.0%Unchanged
Raymond James Financial Services Advisors, Inc.12,031$40.0K0.00%00.0%Unchanged
CFO4Life Group, LLC12,000$40.0K0.01%00.0%Unchanged
Charles Schwab Investment Management Inc11,287$38.0K0.00%00.0%Unchanged
Two Sigma Advisers, LP11,000$37.0K0.00%−600−5.2%Reduced
UBS Group AG7,706$26.0K0.00%−6,701−46.5%Reduced
Steward Partners Investment Advisory, LLC7,700$26.0K0.00%−2,000−20.6%Reduced
Bank of America Corp7,222$24.0K0.00%+4,130+133.6%Added
Institutional & Family Asset Management, LLC3,000$10.0K0.00%00.0%Unchanged
Washington Trust Co2,500$8.00K0.00%00.0%Unchanged
Simplex Trading, LLC2,378$7.00K0.00%+2,178+1,089.0%Added
Royal Bank of Canada1,533$5.00K0.00%00.0%Unchanged
BNP Paribas Arbitrage, SA481$1.62K0.00%00.0%Unchanged
First Manhattan Co500$1.00K0.00%00.0%Unchanged
Westside Investment Management, Inc.200$00.00%00.0%Unchanged
Mark Sheptoff Financial Planning, LLC100$00.00%00.0%Unchanged
Advisor Group Holdings, Inc.10,839––+719+7.1%Added
Sabby Management, LLC0$00.00%−513,211−100.0%Sold out
Geneos Wealth Management Inc.0$00.00%−10,100−100.0%Sold out
Bank Julius Baer & Co. Ltd, Zurich0$00.00%−4,167−100.0%Sold out
Tower Research Capital LLC (TRC)0$00.00%−3,442−100.0%Sold out
Cypress Capital Management LLC (WY)0$00.00%−1,500−100.0%Sold out
Aquatic Capital Management LLC0$00.00%−800−100.0%Sold out
CoreCap Advisors, LLC0$00.00%−133−100.0%Sold out
Harbour Investments, Inc.––––Not filed